US2023082575A1PendingUtilityA1

Slow release pharmaceutical composition made of microparticles

64
Assignee: DEBIOPHARM INT SAPriority: Jun 6, 2007Filed: Sep 15, 2022Published: Mar 16, 2023
Est. expiryJun 6, 2027(~0.9 yrs left)· nominal 20-yr term from priority
A61P 35/00A61P 5/06A61K 9/0019A61K 9/1647A61K 9/19A61K 38/09A61K 47/34
64
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Pharmaceutical composition made of microparticles for the slow release of an active substance at least during a period covering the 6th month after injection of said composition, said composition comprising a group of microparticles made of a copolymer of the PLGA type which incorporate an active substance in the form of a water insoluble peptide salt; said copolymer furthermore comprising at least 75% of lactic acid and an inherent viscosity between 0.1 and 0.9 dl/g, as measured in chloroform at 25° C. and at a polymer concentration of 0.5 g/dL; said microparticles furthermore having a size distribution defined as follows:—D (v,0.1) is between 10 and 30 micrometers,—D (v,0.5) is between 30 and 70 micrometers,—D(v,0.9) is between 50 and 110 micrometers.

Claims

exact text as granted — not AI-modified
1 - 15 . (canceled) 
     
     
         16 . A pharmaceutical composition comprising microparticles comprising 22.5 mg triptorelin in the form of triptorelin pamoate, wherein the microparticles are made of poly(D,L lactide-co-glycolide) (PLGA), wherein the PLGA comprises at least 75% lactide, and wherein the triptorelin pamoate is released from the pharmaceutical composition in an immediate amount within hours following injection into a patient and then constantly released over a period of at least 168 days, wherein the composition comprises two groups of microparticles, wherein the two groups of microparticles are a first group of microgranules and a second group of microgranules. 
     
     
         17 . The pharmaceutical composition of  claim 16 , wherein the first group of microgranules and the second group of microgranules are mixed to have a 50:50 dose ratio of triptorelin. 
     
     
         18 . The pharmaceutical composition of  claim 16 , wherein the pharmaceutical composition is administered to the patient once about every six months. 
     
     
         19 . The pharmaceutical composition of  claim 16 , wherein the PLGA in the first group of microgranules comprises at least 85% lactide.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.